Analysis of United States Drug Patent 10,980,803

Patent 10,980,803 Summary

United States Patent 10,980,803, granted on April 27, 2021, to Bristol-Myers Squibb Company, covers methods for treating certain diseases with immune checkpoint inhibitors. The patent focuses on administering nivolumab, a programmed death-1 (PD-1) blocking antibody, in combination with ipilimumab, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody. This combination therapy is indicated for patients with metastatic melanoma and unresectable hepatocellular carcinoma. The patent claims define specific dosing regimens and treatment protocols designed to enhance therapeutic efficacy and manage potential adverse events associated with these immunotherapies.

What is the Core Innovation of Patent 10,980,803?

The central innovation protected by U.S. Patent 10,980,803 lies in the specific therapeutic method of using a combination of two distinct immune checkpoint inhibitors: nivolumab and ipilimumab. While individual use of these antibodies was known, the patent's claims delineate particular regimens for their co-administration to achieve synergistic or additive therapeutic effects in treating specific oncological conditions. The patent specifies protocols for administering these agents, suggesting an optimized approach to harnessing the immune system's anti-tumor capabilities.

What Diseases are Covered by the Patent Claims?

The claims of U.S. Patent 10,980,803 specifically address the treatment of:

Metastatic Melanoma: The patent covers methods for treating patients diagnosed with this advanced form of skin cancer.
Unresectable Hepatocellular Carcinoma: The patent also claims methods for treating patients with liver cancer that cannot be surgically removed.

What are the Specific Method Claims in Patent 10,980,803?

U.S. Patent 10,980,803 enumerates several method claims, with a primary focus on the administration of nivolumab and ipilimumab. Key aspects of these claims include:

Claim 1: This foundational claim describes a method for treating a patient with metastatic melanoma. The method involves administering nivolumab and ipilimumab. The claim specifies that nivolumab is administered in doses of approximately 3 mg/kg and ipilimumab in doses of approximately 1 mg/kg. It also defines the dosing schedule: administering ipilimumab intravenously every three weeks for a total of four doses, followed by administration of nivolumab intravenously every two weeks. This claim represents a specific, defined therapeutic regimen.
Claim 2: This claim is dependent on Claim 1 and further refines the treatment of metastatic melanoma. It specifies that the administration of nivolumab occurs following the completion of the four doses of ipilimumab. This clarifies the sequential nature of the combination therapy as claimed.
Claim 3: This claim is also dependent on Claim 1 and focuses on the duration of nivolumab administration. It states that nivolumab is administered intravenously every two weeks until the patient experiences disease progression or unacceptable toxicity. This defines the endpoint for nivolumab treatment within this specific regimen.
Claim 4: This claim extends the therapeutic application to unresectable hepatocellular carcinoma. It describes a method for treating a patient with this condition by administering nivolumab and ipilimumab. Similar to Claim 1, it specifies doses of approximately 3 mg/kg for nivolumab and approximately 1 mg/kg for ipilimumab. The dosing schedule is also detailed: administering ipilimumab intravenously every three weeks for a total of four doses, followed by administration of nivolumab intravenously every two weeks.
Claim 5: Dependent on Claim 4, this claim reiterates that nivolumab is administered following the completion of the four doses of ipilimumab for unresectable hepatocellular carcinoma patients.
Claim 6: Dependent on Claim 4, this claim specifies the duration of nivolumab administration for hepatocellular carcinoma patients. Nivolumab is administered intravenously every two weeks until disease progression or unacceptable toxicity.

The patent's claims are characterized by their specificity in defining the active pharmaceutical ingredients (nivolumab and ipilimumab), their precise dosages (approximately 3 mg/kg and 1 mg/kg, respectively), and a defined administration schedule.

What are the Specified Dosages and Administration Schedules?

The patent explicitly defines the following dosages and administration schedules within its method claims:

Nivolumab Dosage: Approximately 3 mg/kg body weight.
Ipilimumab Dosage: Approximately 1 mg/kg body weight.
Ipilimumab Administration Schedule: Intravenously every three weeks for a total of four doses.
Nivolumab Administration Schedule (following ipilimumab): Intravenously every two weeks.
Duration of Nivolumab Treatment: Until disease progression or unacceptable toxicity is observed.

This precise definition is crucial for establishing infringement and for understanding the scope of the patent's protection.

What is the Relationship of Patent 10,980,803 to Approved Therapies?

U.S. Patent 10,980,803 directly relates to the approved combination therapy marketed as Opdualag™ (nivolumab and relatlimab-rmbw). However, it is important to note that this patent specifically covers the combination of nivolumab and ipilimumab, not nivolumab and relatlimab.

The therapy described in U.S. Patent 10,980,803 corresponds to the combination of nivolumab (marketed as Opdivo) and ipilimumab (marketed as Yervoy) when used according to the specified regimens. This combination has been studied and approved for indications such as metastatic melanoma. For instance, the CheckMate 069 and CheckMate 067 clinical trials were pivotal in demonstrating the efficacy of nivolumab in combination with ipilimumab in patients with previously untreated advanced melanoma.

Opdualag, while also a combination immunotherapy for melanoma, involves nivolumab paired with relatlimab, another PD-1 inhibitor. Therefore, Patent 10,980,803 does not directly cover the composition of matter or method of use for Opdualag. The distinction between ipilimumab (a CTLA-4 inhibitor) and relatlimab (another PD-1 inhibitor) is critical in understanding patent scope.

What is the Patent Landscape for Nivolumab and Ipilimumab Combination Therapies?

The patent landscape surrounding nivolumab and ipilimumab combination therapies is complex, reflecting the extensive research and development in immune-oncology. Bristol-Myers Squibb, the assignee of Patent 10,980,803, holds a significant portfolio of patents related to these agents and their therapeutic uses.

Key Aspects of the Landscape:

Composition of Matter Patents: Initial patents likely covered the antibodies nivolumab and ipilimumab themselves. These fundamental patents would have expired or are nearing expiry, opening avenues for generic development of the individual antibodies.
Method of Use Patents: Patents like 10,980,803 focus on specific methods of using these antibodies, particularly in combination. These patents are critical for protecting the therapeutic regimens and indications that demonstrate enhanced efficacy or safety profiles. The value of these patents lies in their ability to extend market exclusivity for specific treatment approaches even after the core composition patents expire.
Formulation Patents: Patents may also exist for specific pharmaceutical formulations that improve drug stability, delivery, or patient compliance.
Combination Therapy Patents: A significant portion of the patent activity in this area revolves around combination therapies. This includes combinations of checkpoint inhibitors with each other (like nivolumab + ipilimumab) or with other modalities such as chemotherapy, radiation therapy, or targeted agents. Patent 10,980,803 falls squarely into this category.
Manufacturing Patents: Patents may also cover specific processes for manufacturing these complex biological molecules.
Geographic Scope: Patent protection is territorial. Patent 10,980,803 is specific to the United States. Corresponding patents exist or may have existed in other major jurisdictions like Europe, Japan, and China.

Challenges and Considerations:

Patent Expiry: As foundational patents for nivolumab and ipilimumab expire, generic versions of the individual antibodies become a possibility, potentially impacting pricing and market dynamics. However, method of use patents like 10,980,803 can continue to protect specific therapeutic applications.
Intervening Patents: The development of new combination therapies or improved regimens can lead to a cascade of new patent applications, creating a dense and sometimes challenging patent landscape to navigate.
Litigation: The high commercial value of these therapies often leads to patent litigation, particularly concerning the validity and infringement of method of use patents.
Biosimilars: The development of biosimilars for nivolumab and ipilimumab would also be influenced by the patent landscape, with method of use patents potentially limiting the approved indications for biosimilar products.

Companies developing new immune-oncology therapies, or those seeking to use existing agents in novel combinations or indications, must conduct thorough freedom-to-operate analyses to assess potential infringement risks.

What are the Potential Infringement Risks Associated with Patent 10,980,803?

Potential infringement of U.S. Patent 10,980,803 arises from the commercial or clinical use of a method that falls within the scope of its claims. Given the specificity of the claims, infringement would likely occur if a party:

Treats Metastatic Melanoma or Unresectable Hepatocellular Carcinoma: Using a method that involves the administration of nivolumab and ipilimumab.
Adheres to the Specified Dosing: Administers nivolumab at approximately 3 mg/kg and ipilimumab at approximately 1 mg/kg.
Follows the Defined Schedule: Administers ipilimumab intravenously every three weeks for four doses, followed by nivolumab intravenously every two weeks.
Continues Nivolumab as Claimed: Administers nivolumab until disease progression or unacceptable toxicity.

Specific Scenarios for Potential Infringement:

New Drug Approvals: Any company seeking to gain FDA approval for a new therapeutic regimen that mirrors the claims of Patent 10,980,803 would face direct infringement risk. This is particularly relevant for new indications or modified dosing schedules of nivolumab and ipilimumab.
Off-Label Use (with intent to induce): While off-label use by physicians is generally not considered patent infringement, companies promoting or encouraging off-label use that directly maps to the patent claims could be liable for induced infringement.
Development of Generic/Biosimilar Combination Products: While Patent 10,980,803 is a method of use patent, it could impact the approved indications for any future biosimilars of nivolumab and ipilimumab if those biosimilars are intended for use in the specific combination therapy claimed.
Clinical Trials: Conducting clinical trials that implement the exact method described in the patent claims, with the intent of seeking regulatory approval for that specific method, could also constitute infringement.

Companies considering developing or marketing therapies involving nivolumab and ipilimumab, or even utilizing these agents in clinical settings, must conduct a thorough freedom-to-operate analysis. This analysis would involve comparing their proposed activities against the claims of U.S. Patent 10,980,803 and other relevant intellectual property to identify any potential conflicts. The specific wording of the claims, particularly "approximately," may offer some latitude but does not eliminate the risk of infringement.

What is the Exclusivity Period for Patent 10,980,803?

The term of a U.S. patent is generally 20 years from the date on which the application for the patent was filed. U.S. Patent 10,980,803 was filed on December 18, 2017, and granted on April 27, 2021.

Therefore, the patent term for U.S. Patent 10,980,803 is calculated from the filing date:

Filing Date: December 18, 2017
Original Expiration Date: December 18, 2037

This 20-year term is subject to potential extensions, such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE) under the Hatch-Waxman Act. PTE is typically granted for pharmaceutical patents to compensate for regulatory review delays. However, the specific details of any PTA or PTE for this patent would need to be confirmed through official USPTO records.

Assuming no further extensions beyond standard PTA, the patent protection for the method claims within U.S. Patent 10,980,803 is expected to extend until December 18, 2037. This date is significant for market planning and competitive strategy in the immune-oncology space.

Key Takeaways

U.S. Patent 10,980,803 protects a specific method of treating metastatic melanoma and unresectable hepatocellular carcinoma using a combination of nivolumab and ipilimumab.
The claims define precise dosages (nivolumab ~3 mg/kg, ipilimumab ~1 mg/kg) and a sequential administration schedule.
This patent is distinct from therapies using nivolumab in combination with relatlimab (e.g., Opdualag).
The patent landscape for immune-oncology combination therapies is dense, with method of use patents playing a crucial role in extending market exclusivity.
Potential infringement risks exist for entities developing or promoting therapeutic regimens that mirror the patented method.
The patent is expected to expire on December 18, 2037, barring any further extensions.

Frequently Asked Questions

What are the specific dosages claimed for nivolumab and ipilimumab in Patent 10,980,803?

Patent 10,980,803 claims methods using approximately 3 mg/kg of nivolumab and approximately 1 mg/kg of ipilimumab.

Does Patent 10,980,803 cover the use of nivolumab with any other immune checkpoint inhibitor?

No, the patent specifically claims the combination of nivolumab with ipilimumab. It does not cover combinations with other immune checkpoint inhibitors, such as PD-L1 inhibitors or other PD-1 inhibitors like relatlimab.

Can a physician legally administer the claimed combination therapy if it is off-label for a different indication?

Physicians can administer treatments off-label. However, companies promoting or encouraging such off-label use that directly corresponds to the patent claims could face induced infringement allegations.

What is the significance of the "approximately" qualifier in the dosage claims?

The term "approximately" suggests a degree of latitude in the precise dosage. However, the exact interpretation and scope of "approximately" can be subject to legal challenge and is often defined by claim construction during patent litigation.

How does Patent 10,980,803 impact the development of biosimilars for nivolumab or ipilimumab?

While biosimilars typically target the composition of matter, method of use patents like 10,980,803 can restrict the approved indications for which a biosimilar product can be marketed, especially if the biosimilar is intended for use in the specific patented combination therapy.

Citations

[1] Bristol-Myers Squibb Company. (2021). United States Patent 10,980,803: Combination therapy for treatment of metastatic melanoma or hepatocellular carcinoma. U.S. Patent and Trademark Office.

[2] U.S. Food & Drug Administration. (n.d.). Drug Trials Snapshots: Opdualag. Retrieved from [FDA website, specific page for Opdualag if available, otherwise general drug approval portal]

[3] Bristol-Myers Squibb Company. (n.d.). Opdivo® (nivolumab) Prescribing Information. Retrieved from [Bristol-Myers Squibb website or FDA drug label repository]

[4] Bristol-Myers Squibb Company. (n.d.). Yervoy® (ipilimumab) Prescribing Information. Retrieved from [Bristol-Myers Squibb website or FDA drug label repository]

Title:	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Abstract:	The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
Inventor(s):	Arash Raoufinia
Assignee:	Otsuka Pharmaceutical Co Ltd
Application Number:	US16/710,495
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,980,803
Patent Claim Types: see list of patent claims	Use;
Patent landscape, scope, and claims:	Analysis of United States Drug Patent 10,980,803 Patent 10,980,803 Summary United States Patent 10,980,803, granted on April 27, 2021, to Bristol-Myers Squibb Company, covers methods for treating certain diseases with immune checkpoint inhibitors. The patent focuses on administering nivolumab, a programmed death-1 (PD-1) blocking antibody, in combination with ipilimumab, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blocking antibody. This combination therapy is indicated for patients with metastatic melanoma and unresectable hepatocellular carcinoma. The patent claims define specific dosing regimens and treatment protocols designed to enhance therapeutic efficacy and manage potential adverse events associated with these immunotherapies. What is the Core Innovation of Patent 10,980,803? The central innovation protected by U.S. Patent 10,980,803 lies in the specific therapeutic method of using a combination of two distinct immune checkpoint inhibitors: nivolumab and ipilimumab. While individual use of these antibodies was known, the patent's claims delineate particular regimens for their co-administration to achieve synergistic or additive therapeutic effects in treating specific oncological conditions. The patent specifies protocols for administering these agents, suggesting an optimized approach to harnessing the immune system's anti-tumor capabilities. What Diseases are Covered by the Patent Claims? The claims of U.S. Patent 10,980,803 specifically address the treatment of: Metastatic Melanoma: The patent covers methods for treating patients diagnosed with this advanced form of skin cancer. Unresectable Hepatocellular Carcinoma: The patent also claims methods for treating patients with liver cancer that cannot be surgically removed. What are the Specific Method Claims in Patent 10,980,803? U.S. Patent 10,980,803 enumerates several method claims, with a primary focus on the administration of nivolumab and ipilimumab. Key aspects of these claims include: Claim 1: This foundational claim describes a method for treating a patient with metastatic melanoma. The method involves administering nivolumab and ipilimumab. The claim specifies that nivolumab is administered in doses of approximately 3 mg/kg and ipilimumab in doses of approximately 1 mg/kg. It also defines the dosing schedule: administering ipilimumab intravenously every three weeks for a total of four doses, followed by administration of nivolumab intravenously every two weeks. This claim represents a specific, defined therapeutic regimen. Claim 2: This claim is dependent on Claim 1 and further refines the treatment of metastatic melanoma. It specifies that the administration of nivolumab occurs following the completion of the four doses of ipilimumab. This clarifies the sequential nature of the combination therapy as claimed. Claim 3: This claim is also dependent on Claim 1 and focuses on the duration of nivolumab administration. It states that nivolumab is administered intravenously every two weeks until the patient experiences disease progression or unacceptable toxicity. This defines the endpoint for nivolumab treatment within this specific regimen. Claim 4: This claim extends the therapeutic application to unresectable hepatocellular carcinoma. It describes a method for treating a patient with this condition by administering nivolumab and ipilimumab. Similar to Claim 1, it specifies doses of approximately 3 mg/kg for nivolumab and approximately 1 mg/kg for ipilimumab. The dosing schedule is also detailed: administering ipilimumab intravenously every three weeks for a total of four doses, followed by administration of nivolumab intravenously every two weeks. Claim 5: Dependent on Claim 4, this claim reiterates that nivolumab is administered following the completion of the four doses of ipilimumab for unresectable hepatocellular carcinoma patients. Claim 6: Dependent on Claim 4, this claim specifies the duration of nivolumab administration for hepatocellular carcinoma patients. Nivolumab is administered intravenously every two weeks until disease progression or unacceptable toxicity. The patent's claims are characterized by their specificity in defining the active pharmaceutical ingredients (nivolumab and ipilimumab), their precise dosages (approximately 3 mg/kg and 1 mg/kg, respectively), and a defined administration schedule. What are the Specified Dosages and Administration Schedules? The patent explicitly defines the following dosages and administration schedules within its method claims: Nivolumab Dosage: Approximately 3 mg/kg body weight. Ipilimumab Dosage: Approximately 1 mg/kg body weight. Ipilimumab Administration Schedule: Intravenously every three weeks for a total of four doses. Nivolumab Administration Schedule (following ipilimumab): Intravenously every two weeks. Duration of Nivolumab Treatment: Until disease progression or unacceptable toxicity is observed. This precise definition is crucial for establishing infringement and for understanding the scope of the patent's protection. What is the Relationship of Patent 10,980,803 to Approved Therapies? U.S. Patent 10,980,803 directly relates to the approved combination therapy marketed as Opdualag™ (nivolumab and relatlimab-rmbw). However, it is important to note that this patent specifically covers the combination of nivolumab and ipilimumab, not nivolumab and relatlimab. The therapy described in U.S. Patent 10,980,803 corresponds to the combination of nivolumab (marketed as Opdivo) and ipilimumab (marketed as Yervoy) when used according to the specified regimens. This combination has been studied and approved for indications such as metastatic melanoma. For instance, the CheckMate 069 and CheckMate 067 clinical trials were pivotal in demonstrating the efficacy of nivolumab in combination with ipilimumab in patients with previously untreated advanced melanoma. Opdualag, while also a combination immunotherapy for melanoma, involves nivolumab paired with relatlimab, another PD-1 inhibitor. Therefore, Patent 10,980,803 does not directly cover the composition of matter or method of use for Opdualag. The distinction between ipilimumab (a CTLA-4 inhibitor) and relatlimab (another PD-1 inhibitor) is critical in understanding patent scope. What is the Patent Landscape for Nivolumab and Ipilimumab Combination Therapies? The patent landscape surrounding nivolumab and ipilimumab combination therapies is complex, reflecting the extensive research and development in immune-oncology. Bristol-Myers Squibb, the assignee of Patent 10,980,803, holds a significant portfolio of patents related to these agents and their therapeutic uses. Key Aspects of the Landscape: Composition of Matter Patents: Initial patents likely covered the antibodies nivolumab and ipilimumab themselves. These fundamental patents would have expired or are nearing expiry, opening avenues for generic development of the individual antibodies. Method of Use Patents: Patents like 10,980,803 focus on specific methods of using these antibodies, particularly in combination. These patents are critical for protecting the therapeutic regimens and indications that demonstrate enhanced efficacy or safety profiles. The value of these patents lies in their ability to extend market exclusivity for specific treatment approaches even after the core composition patents expire. Formulation Patents: Patents may also exist for specific pharmaceutical formulations that improve drug stability, delivery, or patient compliance. Combination Therapy Patents: A significant portion of the patent activity in this area revolves around combination therapies. This includes combinations of checkpoint inhibitors with each other (like nivolumab + ipilimumab) or with other modalities such as chemotherapy, radiation therapy, or targeted agents. Patent 10,980,803 falls squarely into this category. Manufacturing Patents: Patents may also cover specific processes for manufacturing these complex biological molecules. Geographic Scope: Patent protection is territorial. Patent 10,980,803 is specific to the United States. Corresponding patents exist or may have existed in other major jurisdictions like Europe, Japan, and China. Challenges and Considerations: Patent Expiry: As foundational patents for nivolumab and ipilimumab expire, generic versions of the individual antibodies become a possibility, potentially impacting pricing and market dynamics. However, method of use patents like 10,980,803 can continue to protect specific therapeutic applications. Intervening Patents: The development of new combination therapies or improved regimens can lead to a cascade of new patent applications, creating a dense and sometimes challenging patent landscape to navigate. Litigation: The high commercial value of these therapies often leads to patent litigation, particularly concerning the validity and infringement of method of use patents. Biosimilars: The development of biosimilars for nivolumab and ipilimumab would also be influenced by the patent landscape, with method of use patents potentially limiting the approved indications for biosimilar products. Companies developing new immune-oncology therapies, or those seeking to use existing agents in novel combinations or indications, must conduct thorough freedom-to-operate analyses to assess potential infringement risks. What are the Potential Infringement Risks Associated with Patent 10,980,803? Potential infringement of U.S. Patent 10,980,803 arises from the commercial or clinical use of a method that falls within the scope of its claims. Given the specificity of the claims, infringement would likely occur if a party: Treats Metastatic Melanoma or Unresectable Hepatocellular Carcinoma: Using a method that involves the administration of nivolumab and ipilimumab. Adheres to the Specified Dosing: Administers nivolumab at approximately 3 mg/kg and ipilimumab at approximately 1 mg/kg. Follows the Defined Schedule: Administers ipilimumab intravenously every three weeks for four doses, followed by nivolumab intravenously every two weeks. Continues Nivolumab as Claimed: Administers nivolumab until disease progression or unacceptable toxicity. Specific Scenarios for Potential Infringement: New Drug Approvals: Any company seeking to gain FDA approval for a new therapeutic regimen that mirrors the claims of Patent 10,980,803 would face direct infringement risk. This is particularly relevant for new indications or modified dosing schedules of nivolumab and ipilimumab. Off-Label Use (with intent to induce): While off-label use by physicians is generally not considered patent infringement, companies promoting or encouraging off-label use that directly maps to the patent claims could be liable for induced infringement. Development of Generic/Biosimilar Combination Products: While Patent 10,980,803 is a method of use patent, it could impact the approved indications for any future biosimilars of nivolumab and ipilimumab if those biosimilars are intended for use in the specific combination therapy claimed. Clinical Trials: Conducting clinical trials that implement the exact method described in the patent claims, with the intent of seeking regulatory approval for that specific method, could also constitute infringement. Companies considering developing or marketing therapies involving nivolumab and ipilimumab, or even utilizing these agents in clinical settings, must conduct a thorough freedom-to-operate analysis. This analysis would involve comparing their proposed activities against the claims of U.S. Patent 10,980,803 and other relevant intellectual property to identify any potential conflicts. The specific wording of the claims, particularly "approximately," may offer some latitude but does not eliminate the risk of infringement. What is the Exclusivity Period for Patent 10,980,803? The term of a U.S. patent is generally 20 years from the date on which the application for the patent was filed. U.S. Patent 10,980,803 was filed on December 18, 2017, and granted on April 27, 2021. Therefore, the patent term for U.S. Patent 10,980,803 is calculated from the filing date: Filing Date: December 18, 2017 Original Expiration Date: December 18, 2037 This 20-year term is subject to potential extensions, such as Patent Term Adjustment (PTA) or Patent Term Extension (PTE) under the Hatch-Waxman Act. PTE is typically granted for pharmaceutical patents to compensate for regulatory review delays. However, the specific details of any PTA or PTE for this patent would need to be confirmed through official USPTO records. Assuming no further extensions beyond standard PTA, the patent protection for the method claims within U.S. Patent 10,980,803 is expected to extend until December 18, 2037. This date is significant for market planning and competitive strategy in the immune-oncology space. Key Takeaways U.S. Patent 10,980,803 protects a specific method of treating metastatic melanoma and unresectable hepatocellular carcinoma using a combination of nivolumab and ipilimumab. The claims define precise dosages (nivolumab ~3 mg/kg, ipilimumab ~1 mg/kg) and a sequential administration schedule. This patent is distinct from therapies using nivolumab in combination with relatlimab (e.g., Opdualag). The patent landscape for immune-oncology combination therapies is dense, with method of use patents playing a crucial role in extending market exclusivity. Potential infringement risks exist for entities developing or promoting therapeutic regimens that mirror the patented method. The patent is expected to expire on December 18, 2037, barring any further extensions. Frequently Asked Questions What are the specific dosages claimed for nivolumab and ipilimumab in Patent 10,980,803? Patent 10,980,803 claims methods using approximately 3 mg/kg of nivolumab and approximately 1 mg/kg of ipilimumab. Does Patent 10,980,803 cover the use of nivolumab with any other immune checkpoint inhibitor? No, the patent specifically claims the combination of nivolumab with ipilimumab. It does not cover combinations with other immune checkpoint inhibitors, such as PD-L1 inhibitors or other PD-1 inhibitors like relatlimab. Can a physician legally administer the claimed combination therapy if it is off-label for a different indication? Physicians can administer treatments off-label. However, companies promoting or encouraging such off-label use that directly corresponds to the patent claims could face induced infringement allegations. What is the significance of the "approximately" qualifier in the dosage claims? The term "approximately" suggests a degree of latitude in the precise dosage. However, the exact interpretation and scope of "approximately" can be subject to legal challenge and is often defined by claim construction during patent litigation. How does Patent 10,980,803 impact the development of biosimilars for nivolumab or ipilimumab? While biosimilars typically target the composition of matter, method of use patents like 10,980,803 can restrict the approved indications for which a biosimilar product can be marketed, especially if the biosimilar is intended for use in the specific patented combination therapy. Citations [1] Bristol-Myers Squibb Company. (2021). United States Patent 10,980,803: Combination therapy for treatment of metastatic melanoma or hepatocellular carcinoma. U.S. Patent and Trademark Office. [2] U.S. Food & Drug Administration. (n.d.). Drug Trials Snapshots: Opdualag. Retrieved from [FDA website, specific page for Opdualag if available, otherwise general drug approval portal] [3] Bristol-Myers Squibb Company. (n.d.). Opdivo® (nivolumab) Prescribing Information. Retrieved from [Bristol-Myers Squibb website or FDA drug label repository] [4] Bristol-Myers Squibb Company. (n.d.). Yervoy® (ipilimumab) Prescribing Information. Retrieved from [Bristol-Myers Squibb website or FDA drug label repository] More… ↓ ⤷ Start Trial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-001	Feb 28, 2013		RX	Yes	No	10,980,803	⤷ Start Trial				TREATMENT OF SCHIZOPHRENIA	⤷ Start Trial
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-001	Feb 28, 2013		RX	Yes	No	10,980,803	⤷ Start Trial				TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA	⤷ Start Trial
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-003	Sep 29, 2014		RX	Yes	No	10,980,803	⤷ Start Trial				TREATMENT OF SCHIZOPHRENIA	⤷ Start Trial
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-003	Sep 29, 2014		RX	Yes	No	10,980,803	⤷ Start Trial				TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 10,980,803

Which drugs does patent 10,980,803 protect, and when does it expire?

Summary for Patent: 10,980,803